Episode 167: George Yancopoulos on biotech in 2021, plus a CRISPR milestone, Biogen's FDA saga,

First we talk to George Yancopoulos, head scientist at Regeneron Pharmaceuticals, about the future of CRISPR genome editing and the latest idea for treating obesity. Then, we discuss STAT's reporting on the cozy relationship between Biogen and the FDA ahead of Aduhelm's approval and what the ensuing fallout might mean. Before all that, we chat about the latest news in biotech, including vaccine boosters and a decadelong debacle.

Om Podcasten

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.